Difficulty: Medium
Average Score: 93%
Practice
A 5-year-old boy has systemic juvenile idiopathic arthritis (sJIA) with systemic manifestations including fever, hepatosplenomegaly, and pericarditis. Of the following, the BEST initial treatment for this boy is
Correct answer
B
Rationale
In treating a 5-year-old boy with systemic juvenile idiopathic arthritis (sJIA) presenting with systemic manifestations like fever, hepatosplenomegaly, and pericarditis, the BEST initial treatment is systemic glucocorticoids (Option B).
Systemic glucocorticoids are the preferred initial therapy in sJIA due to their potent anti-inflammatory effects. They help to rapidly control inflammation and alleviate symptoms, especially in cases of systemic involvement like pericarditis.
NSAIDs (Option A) are commonly used in managing arthritis symptoms but may not be sufficient for systemic manifestations in sJIA. TNF-a inhibitors (Option C) and IL-1 antagonists (Option D) are typically reserved for cases refractory to glucocorticoids or with specific indications, not as initial therapy.
Educationally, understanding the rationale behind choosing systemic glucocorticoids as the initial treatment in sJIA is crucial for pediatric healthcare providers. It underscores the importance of prompt and effective management of systemic inflammation in these patients to prevent long-term complications and improve outcomes. Familiarity with appropriate treatment strategies in pediatric rheumatologic conditions is essential for providing quality care to children with complex autoimmune diseases.
Systemic glucocorticoids are the preferred initial therapy in sJIA due to their potent anti-inflammatory effects. They help to rapidly control inflammation and alleviate symptoms, especially in cases of systemic involvement like pericarditis.
NSAIDs (Option A) are commonly used in managing arthritis symptoms but may not be sufficient for systemic manifestations in sJIA. TNF-a inhibitors (Option C) and IL-1 antagonists (Option D) are typically reserved for cases refractory to glucocorticoids or with specific indications, not as initial therapy.
Educationally, understanding the rationale behind choosing systemic glucocorticoids as the initial treatment in sJIA is crucial for pediatric healthcare providers. It underscores the importance of prompt and effective management of systemic inflammation in these patients to prevent long-term complications and improve outcomes. Familiarity with appropriate treatment strategies in pediatric rheumatologic conditions is essential for providing quality care to children with complex autoimmune diseases.